Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 05/26 10:01:44 pm
112.9 USD   -0.40%
05/26 JOHNSON & JOHNS : Pharma company developing cancer drug moving to Ho..
05/25 JOHNSON & JOHNS : to Participate in the Goldman Sachs 37th Annual Gl..
05/25 AGS : Pelvic mesh implants caused dire complications
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on JOHNSON & JOHNSON
05/26 JOHNSON & JOHNSON : Pharma company developing cancer drug moving to Houston
05/25 JOHNSON & JOHNSON : to Participate in the Goldman Sachs 37th Annual Global Healt..
05/25 AGS : Pelvic mesh implants caused dire complications
05/25DJJOHNSON & JOHNSON : Washington, California Sue Johnson & Johnson Over Vaginal Me..
05/24 JOHNSON & JOHNSON : Healthcare Sector Stock Business Review
05/24 JOHNSON & JOHNSON : U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/met..
05/24 JOHNSON & JOHNSON : Washington, California sue over pelvic mesh implants
05/24 JOHNSON & JOHNSON : New Phase 3 Study Findings Show STELARA® Maintained Clinical..
05/23DJSAMSUNG ELECTRONICS : Targets U.S. Drug Market With Remicade Knockoff
05/23 JOHNSON & JOHNSON : Boomer Esiason Foundation Announces Collaboration with Johns..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials